Pemigatinb

Phase 2

HHaitao Zhao, MD

Pemigatinb is one of 8 therapeutic programs targeting Biliary Tract Cancer (BTC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Biliary Tract Cancer (BTC)Recruiting

Biliary Tract Cancer (BTC)Phase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Biliary Tract Cancer (BTC)

#DrugCompanyPhaseTrials

Zaniducla

Jazz Pharmaceuticals

Phase 3

1 2

Lytgobi

Taiho Oncology, Inc.

Phase 3

1 3

Tibsovo

SServier

Phase 3

1 4

Gemzar

Johnson & Johnson

Phase 2

2 5

PD-1 Inhibitors

BBioNTech US Inc.

Phase 2

1 6

Iparomlimab and Tuvonralimab

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 7

Pemigatinb

HHaitao Zhao, MD

Phase 2

1 8

PD-1 and Chemotherapy

TTongji University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Biliary Tract Cancer (BTC)

NCT07786766

Clinical

Trials by Indication[1]

Biliary Tract Cancer (BTC)1 trial

An Open-Label, Phase II Clinical Study Evaluating the Efficacy and Safety of Pemigatinib in Combination With a PD-1 Inhibitor, With or Without Chemotherapy, in Patients With Unresectable or Metastatic Cholangiocarcinoma Harboring FGFR2 Fusions or Rearrangements

Recruiting·HHaitao Zhao, MD·Phase 2·NCT07786766·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pemigatinb. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pemigatinb. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Haitao Zhao, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: HHaitao Zhao, MD

Pemigatinb

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Biliary Tract Cancer (BTC)1 trial

References

Drug Info

Quick Facts

Related News